Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 22,004 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Hearing Aids, Hearing Loss, Bilateral Sensorineural, 3D Printing
Interventions: BTE hearing aids with compatible ear tips (Third-party, FlexResin, Resin), BTE hearing aids with compatible ear tips (FlexResin, Resin, Third-party, FlexResin), BTE hearing aids with compatible ear tips (Resin, Third-party, FlexRes); Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 89 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Dyspepsia
Interventions: Alimetry, tVNS, Gastroduodenal Manometry; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hemodialysis, Clinical Assessment
Interventions: PatenSee System; Device
Lead sponsor: PatenSee Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions: Relugolix and Enzalutamide; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older · Male only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Risk Perceptions, Decision Making, Alcohol
Interventions: Health warning statement evaluations (bottles), Health warning statement evaluations (ads); Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Manuel Monreal; Other
Eligibility: Not listed
Enrollment: 120,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2027
U.S. locations: 6
States / cities: New Haven, Connecticut • Jacksonville, Florida • Evanston, Illinois + 3 more

Conditions: CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
Interventions: Standard of Care Antiviral medications, Viral CTLs; Drug · Biological
Lead sponsor: New York Medical College; Other
Eligibility: 1 Day to 30 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Valhalla, New York • Milwaukee, Wisconsin

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Durvalumab, Placebo to MK-1084; Drug · Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 6
States / cities: Savannah, Georgia • Lisle, Illinois • Lincoln, Nebraska + 3 more

Conditions: Traumatic Spinal Cord Injuries
Interventions: Normobaric Hyperoxia; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Temporomandibular Disorder
Interventions: Transcutaneous Auricular Neurostimulation, Sham Stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
Interventions: SB-007; Genetic
Lead sponsor: Splice Bio; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: No Disease or Condition is Being Studied, Stress (Psychology)
Interventions: K-Savvy, Healthy Living; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia, Paget Disease of Bone, Frontotemporal Dementia, Myopathy
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2030
U.S. locations: 1
States / cities: Irvine, California

Conditions: Aortic Stenosis
Interventions: Pelacarsen (TQJ230) 80mg, Matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 35
States / cities: Huntsville, Alabama • Beverly Hills, California • Covina, California + 26 more

Conditions: Smoking Cessation, Tobacco Use Disorder
Interventions: Cytisinicline, Placebo Oral Capsule; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ulcerative Colitis (UC)
Interventions: Ponesimod, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chula Vista, California • Nashville, Tennessee

Conditions: Dietary Modification, Cardiovascular Risk Factor
Interventions: MeLT Dietary intervention, TLC Dietary intervention, MeLT dietary intervention with TMAO; Behavioral
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tinea Pedis
Interventions: 1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C; Drug
Lead sponsor: Propedix, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Framingham, Massachusetts • Milford, Massachusetts

Conditions: Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
Interventions: PF-08634404, Chemotherapy, Nivolumab; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 83
States / cities: Atascadero, California • Burbank, California • Encino, California + 68 more

Conditions: Lung Cancer
Interventions: Biopsy of the major carinal area, Biopsy of abnormal & suspicious areas of the bronchial tree, Evaluation of the tumor for DNA mutations, Bronchoalveolar Lavage (BAL) for cytokine analysis, Correlation of flow cytometric & RT PCR for TNM stage, Analysis of lymph nodes; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2050
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cancer Survivorship, Chemotherapy Side Effects
Interventions: Social Cognitive Theory-based, Technology-delivered Physical Activity Program; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: High Blood Pressure
Interventions: CardioCare Quest; Behavioral
Lead sponsor: Northern Arizona University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Flagstaff, Arizona

Conditions: Lung Transplant Rejection
Interventions: Belumosudil, Azithromycin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Homelessness
Interventions: Street medicine follow up; Behavioral
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Effectiveness Comparison of 3D-Printed and Conventional Ear Tip Comfort in Individuals With Hearing Loss

High Resolution Gastric Mapping and Gastroduodenal Manometry

Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Designing Effective Alcohol Health Warnings: An Experimental Study With Adults in the U.S.

Computerized Registry of Patients With Venous Thromboembolism (RIETE)

Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

Treating Spinal Cord Injury With Early Normobaric Hyperoxia

Evaluating Noninvasive Brain Stimulation for TMD Pain: A Feasibility Study

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Caring for Dementia Caregivers in Ethnic Immigrant Communities

Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

Examining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity

Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)

Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Detection of Genetic Markers of Lung Cancer

Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes

CardioCare Quest: A Co-created Game for Improving Hypertension Treatment Compliance in Arizona

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Emergency Department Linkage to Care for Patients Experiencing Homelessness